Figure 4. Progression free survival (PFS) (A) and overall survival (OS) (B) in patients with wild-type or heterozygous genotypes (NER pathway “proficient”) and in patients with homozygous mutant variant in at least one of the five SNPs (NER pathway “deficient”).